Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients

BACKGROUND: Kidney transplantation is the therapy of choice for many patients with end‐stage kidney disease (ESKD) with an improvement in survival rates and satisfactory short term graft survival. However, there has been little improvement in long‐term survival. The place of target of rapamycin inhi...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cochrane Database Syst Rev
Egile Nagusiak: Hahn, Deirdre, Hodson, Elisabeth M, Hamiwka, Lorraine A, Lee, Vincent WS, Chapman, Jeremy R, Craig, Jonathan C, Webster, Angela C
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley & Sons, Ltd 2019
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6953317/
https://ncbi.nlm.nih.gov/pubmed/31840244
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD004290.pub3
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak